Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alembic Pharmaceuticals Ltd.

NSE: APLLTD | BSE: 533573 | ISIN: INE901L01018 | Industry: Pharmaceuticals
| Mid-range Performer

859.9000 11.65 (1.37%)

NSE Dec 19, 2025 15:31 PM

Volume: 65,161

Alembic Pharmaceuticals Ltd.

07 May 2025

859.90

1.37%

Alembic Pharma (BUY): FY26 to be better than FY25

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25

Alembic Pharmaceutic.. has an average target of 1028.50 from 4 brokers.